Lenalidomida Teva (Lenalidomide)

Lenalidomide binds to the cereblon protein within the CRL4CRBN E3 ubiquitin ligase complex, changing its substrate specificity. This triggers the degradation of transcription factors Ikaros and Aiolos, leading to enhanced immune cell activity, inhibition of new blood vessel formation, and direct anti‑tumor effects that suppress malignant plasma cells.

The specific dose and schedule of Lenalidomida Teva are determined by the prescribing physician based on the patient’s diagnosis, disease stage, renal function, and other clinical factors. Healthcare providers tailor the regimen to achieve optimal therapeutic benefit while minimizing risk.

Lenalidomida Teva is classified as pregnancy category X because it can cause severe fetal harm, including birth defects. It is contraindicated in pregnant women and should not be used by women who are breastfeeding, as the drug may be excreted in breast milk and affect the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lenalidomida Teva belongs to the immunomodulatory drug class, offering a distinct mechanism compared with proteasome inhibitors or monoclonal antibodies. It provides oral administration, which can be more convenient, and has demonstrated efficacy in relapsed or refractory multiple myeloma, often used in combination regimens to enhance response rates.

Lenalidomida Teva should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Lenalidomida Teva is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets are swallowed whole with a glass of water, and the dosing schedule (e.g., daily or on specific days of a cycle) is individualized for each patient.

The most serious risks include severe neutropenia and thrombocytopenia, which can lead to infections or bleeding, as well as venous thromboembolism, embryo‑fetal toxicity, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for these events throughout therapy.

Lenalidomida Teva is contraindicated in pregnant women and in individuals with known hypersensitivity to lenalidomide or any component of the formulation. Caution is also advised for patients with severe renal impairment, uncontrolled infections, or a history of thromboembolic events unless appropriate prophylaxis is in place.